Business Context and Reporting Period
This Form 8-K, filed on December 10, 2020, reports that Aytu BioScience, Inc. ("Aytu") entered into a definitive Agreement and Plan of Merger with Neos Therapeutics, Inc. ("Neos"). Under the agreement, a wholly-owned subsidiary of Aytu will merge with Neos, with Neos surviving as a wholly-owned subsidiary of Aytu. The filing also details related financing arrangements, debt consents, and voting agreements executed on the same date.
Key Financial Metrics and Transaction Terms
- Exchange Ratio: Neos shareholders will receive 0.1088 shares of Aytu common stock for each share of Neos common stock held, subject to adjustments.
- Bridge Financing: Aytu committed to provide Neos with an unsecured convertible note up to $5,000,000. Interest accrues at 6.0% per annum, compounding monthly starting January 2021, with a maturity date of November 7, 2022.
- Debt Prepayment: Upon closing the Merger, Aytu must prepay $15,000,000 of the principal under Neos's existing Deerfield Facility Agreement.
- Termination Fee: A termination fee of $2,000,000 may be payable by either party under specific circumstances outlined in the Merger Agreement.
- Liquidity and Going Concern: Neos's financial statements for periods ending June 30, 2020, and September 30, 2020, contained "going concern" qualifications. Lenders have agreed to waive defaults related to these qualifications pending the Merger's consummation or termination.
Material Changes and Conditions
The filing represents a material change in corporate structure and capitalization. The Merger is subject to several closing conditions, including:
- Adoption of the Merger Agreement by a majority of Neos stockholders.
- Approval of the issuance of Aytu common stock by a majority of Aytu stockholders.
- Satisfaction of conditions related to Neos's existing debt facilities (Deerfield and Encina).
- Absence of a material adverse effect on either party.
The Bridge Note Adjustment mechanism will reduce the Exchange Ratio by 0.0001 for every $100,000 of bridge financing funded by Aytu.
Guidance, Outlook, and Risks
Outlook and Timeline: The Merger Agreement includes an "Outside Date" of September 10, 2021, by which the transaction must be completed or it may be terminated. Aytu expects to file a joint proxy statement/prospectus on Form S-4 with the SEC.
Risks and Contingencies:
- Transaction Failure: Risks include failure to obtain required shareholder votes, regulatory prohibitions, or termination by either party.
- Financial Distress: Neos has faced substantial doubt regarding its ability to continue as a going concern, necessitating waivers from lenders.
- Integration: Risks related to the diversion of management time and the ability to realize anticipated synergies.
- Forward-Looking Statements: The filing contains predictions regarding the transaction's timetable and results, which are subject to uncertainties.
Investor Verification Checklist
- Verify the final Exchange Ratio, as it is subject to adjustment based on the utilization of the $5,000,000 bridge financing.
- Confirm the outcome of the shareholder votes required from both Aytu and Neos stockholders.
- Review the upcoming Form S-4 joint proxy statement/prospectus for detailed financial data and risk factors not fully disclosed in this 8-K.
- Monitor the status of the "going concern" waivers from Deerfield Lenders and Encina Business Credit, LLC, as these are critical to closing.
- Assess the impact of the $15,000,000 debt prepayment requirement on Aytu's liquidity upon closing.